That's gonna leave a markA few notes from the weekend that was ...
- Satisfaction Gauranteed! Can pharmaceutical firms profit with variations on the no-cure-no-pay strategy? The New York Times takes a look. Incidentally, if that sounds familiar you may have read another take on that issue on the IN VIVO Blog about six weeks ago ... and there'll be more in the next issue of IN VIVO.
- Accept No Substitutes! The San Francisco Chronicle reviews the pros and cons of generic biologics. Biosimilars? Biogenerics? Whatever you're calling them these days.
- For Refined Tastes! Tom Wolfe won't be reading this. And IN VIVO Blog thinks white suits look pretty damn silly, so we're even.
- Breaking Hearts Since 1883! The Philadelphia Phillies, favorite baseball team of a few of us at the IN VIVO Blog, lost their record 10,000th game last night, falling to the Cardinals 10-2. That ignominious milestone got us thinking ... is there a parallel in the pharmaceutical world, a company with a particularly striking blend of poor luck and staying power (and bad pitching)?
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.